JERUSALEM & TARRYTOWN, N.Y.-- --Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd. today provided an update on fasinumab, triggered by a recent development in a Phase 2b fasinumab study in patients with chronic low back pain. Fasinumab is an investigational Nerve Growth Factor antibody in clinical development for osteoarthritis pain and chronic low back pain.
http://ift.tt/2dvSRFI
No comments:
Post a Comment